SCHEMBL26075411

SCHEMBL26075411

CCOc1ccc(-c2ccc(-c3cc(C)c4cc(C(F)(F)F)ccc4n3)cc2F)c(F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HMOX1 P09601 3/20 0.42
▸ KDM4E B2RXH2 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ LMNA P02545 2/20 0.39
▸ TP53 P04637 1/20 0.39
▸ FEN1 P39748 5/20 0.39
▸ ALOX5AP P20292 4/20 0.39
▸ ACP1 P24666 1/20 0.39
▸ SLC2A1 P11166 1/20 0.39
▸ MCHR1 Q99705 1/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ PPARD Q03181 2/20 0.38
▸ PDE2A O00408 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ HTR2B P41595 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26075292 0.94 FEN1 (0.41) HMOX1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL26075379 0.90 PTGS2 (0.44) HMOX1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL26075298 0.87 HMOX1 (0.45) HMOX1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL26075393 0.87 PDE10A (0.43) TP53FEN1ALOX5AP
SCHEMBL26075973 0.86 FEN1 (0.39) LMNATP53FEN1ALOX5APACP1
SCHEMBL23590135 0.86 KDM4E (0.58) KDM4ESMN1; SMN2MEN1KMT2AHSD17B10
SCHEMBL26074055 0.86 LMNA (0.47) KDM4ESMN1; SMN2HSD17B10LMNATP53
SCHEMBL26075888 0.85 HMOX1 (0.43) HMOX1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL26075355 0.84 PDE2A (0.45) FEN1ALOX5APMCHR1PPARDPDE2A
SCHEMBL26075335 0.84 ACP1 (0.50) KDM4ELMNAFEN1ALOX5APACP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD HMOX1 329/4885KDM4E 1396/4885SMN1; SMN2 3677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback